Risk factors for early IA (up to 40 days after transplantation) and late IA (days 41-180 after transplantation)
| . | Early IA (n = 57) . | Late IA (n = 99) . | ||||
|---|---|---|---|---|---|---|
| Cases, no. (%) . | HR . | 95% CI . | Cases, no. (%) . | HR . | 95% CI . | |
| Recipient-related factors | ||||||
| Age, y | ||||||
| Younger than 19 | 5 (8.8) | 1.0 | — | 12 (12.1) | — | — |
| 19-40 | 21 (36.8) | 3.8 | 1.3-11.23-155 | 34 (34.3) | NS | NS |
| Older than 40 | 31 (54.4) | 5.9 | 2.0-17.43-154 | 53 (53.5) | — | — |
| Underlying disease3-150 | ||||||
| CML, chronic phase | 3 (5.3) | 1.0 | — | 24 (24.2) | 1.0 | — |
| Hematologic malignancy, first remission | 5 (8.8) | 4.4 | 1.0-18.83-155 | 6 (6.1) | — | NS |
| Hematologic malignancy, other | 31 (54.4) | 6.9 | 2.1-23.13-155 | 37 (37.4) | — | NS |
| Aplastic anemia | 2 (3.5) | 8.3 | 1.4-50.63-155 | 2 (2.0) | — | NS |
| Myelodysplastic syndrome | 9 (15.8) | 6.0 | 1.6-22.43-155 | 13 (13.1) | — | NS |
| Multiple myeloma | 2 (3.5) | — | NS | 13 (13.1) | 4.5 | 2.3-9.13-154 |
| CMV serostatus3-151 | ||||||
| D−/R− | 14 (24.6) | — | — | 20 (20.2) | 1.0 | — |
| D+/R− | 5 (8.8) | NS | NS | 17 (17.2) | 2.0 | 1.0-3.73-155 |
| D−/R+ | 17 (29.8) | — | — | 30 (30.3) | 2.0 | 1.1-3.73-155 |
| D+/R+ | 21 (36.8) | — | — | 32 (32.3) | — | NS |
| Transplant-related factors (donor and stem cell source) | ||||||
| MR BM | 17 (29.8) | 1.0 | — | 31 (31.3) | — | — |
| MR PBSCs | 2 (3.5) | 0.2 | 0.05-0.93-155 | 12 (12.1) | — | — |
| MM/UR BM | 32 (56.1) | — | NS | 53 (53.5) | NS | NS |
| MM/UR PBSCs | 3 (5.3) | — | NS | 3 (3.0) | — | — |
| Cord blood | 3 (5.3) | 13.5 | 3.3-55.53-154 | 0 | — | — |
| T cell–depleted/CD34-selected | 6 (10.5) | — | NS | 9 (9.1) | 3.4 | 1.7-7.03-154 |
| Transplant complications | ||||||
| Neutropenia3-152 | — | — | — | — | 2.6 | 1.4-4.83-155 |
| Lymphopenia3-152 | — | — | — | — | 2.0 | 1.1-3.83-155 |
| GVHD, acute3-152,3-153 | ||||||
| Grades 0-1 | — | — | — | — | 1.0 | — |
| Grades 2-4 | — | — | — | — | 10.6 | 2.6-43.43-154 |
| Missing | — | — | — | — | 10.6 | 2.2-52.13-155 |
| GVHD, chronic (clinically extensive)3-152,3-153 | — | — | — | — | — | NS |
| CMV disease3-152 | — | 26.3 | 9.6-72.03-154 | — | 10.2 | 5.4-19.53-154 |
| Respiratory virus infection3-152 | — | — | NS | — | 2.1 | 1.1-3.83-155 |
| . | Early IA (n = 57) . | Late IA (n = 99) . | ||||
|---|---|---|---|---|---|---|
| Cases, no. (%) . | HR . | 95% CI . | Cases, no. (%) . | HR . | 95% CI . | |
| Recipient-related factors | ||||||
| Age, y | ||||||
| Younger than 19 | 5 (8.8) | 1.0 | — | 12 (12.1) | — | — |
| 19-40 | 21 (36.8) | 3.8 | 1.3-11.23-155 | 34 (34.3) | NS | NS |
| Older than 40 | 31 (54.4) | 5.9 | 2.0-17.43-154 | 53 (53.5) | — | — |
| Underlying disease3-150 | ||||||
| CML, chronic phase | 3 (5.3) | 1.0 | — | 24 (24.2) | 1.0 | — |
| Hematologic malignancy, first remission | 5 (8.8) | 4.4 | 1.0-18.83-155 | 6 (6.1) | — | NS |
| Hematologic malignancy, other | 31 (54.4) | 6.9 | 2.1-23.13-155 | 37 (37.4) | — | NS |
| Aplastic anemia | 2 (3.5) | 8.3 | 1.4-50.63-155 | 2 (2.0) | — | NS |
| Myelodysplastic syndrome | 9 (15.8) | 6.0 | 1.6-22.43-155 | 13 (13.1) | — | NS |
| Multiple myeloma | 2 (3.5) | — | NS | 13 (13.1) | 4.5 | 2.3-9.13-154 |
| CMV serostatus3-151 | ||||||
| D−/R− | 14 (24.6) | — | — | 20 (20.2) | 1.0 | — |
| D+/R− | 5 (8.8) | NS | NS | 17 (17.2) | 2.0 | 1.0-3.73-155 |
| D−/R+ | 17 (29.8) | — | — | 30 (30.3) | 2.0 | 1.1-3.73-155 |
| D+/R+ | 21 (36.8) | — | — | 32 (32.3) | — | NS |
| Transplant-related factors (donor and stem cell source) | ||||||
| MR BM | 17 (29.8) | 1.0 | — | 31 (31.3) | — | — |
| MR PBSCs | 2 (3.5) | 0.2 | 0.05-0.93-155 | 12 (12.1) | — | — |
| MM/UR BM | 32 (56.1) | — | NS | 53 (53.5) | NS | NS |
| MM/UR PBSCs | 3 (5.3) | — | NS | 3 (3.0) | — | — |
| Cord blood | 3 (5.3) | 13.5 | 3.3-55.53-154 | 0 | — | — |
| T cell–depleted/CD34-selected | 6 (10.5) | — | NS | 9 (9.1) | 3.4 | 1.7-7.03-154 |
| Transplant complications | ||||||
| Neutropenia3-152 | — | — | — | — | 2.6 | 1.4-4.83-155 |
| Lymphopenia3-152 | — | — | — | — | 2.0 | 1.1-3.83-155 |
| GVHD, acute3-152,3-153 | ||||||
| Grades 0-1 | — | — | — | — | 1.0 | — |
| Grades 2-4 | — | — | — | — | 10.6 | 2.6-43.43-154 |
| Missing | — | — | — | — | 10.6 | 2.2-52.13-155 |
| GVHD, chronic (clinically extensive)3-152,3-153 | — | — | — | — | — | NS |
| CMV disease3-152 | — | 26.3 | 9.6-72.03-154 | — | 10.2 | 5.4-19.53-154 |
| Respiratory virus infection3-152 | — | — | NS | — | 2.1 | 1.1-3.83-155 |
Calculated on the basis of 1625 evaluable control patients and 57 cases during the early period and 1526 evaluable control patients and 99 cases during the late period. Hazard ratios (HRs) and 95% confidence intervals (CIs) are shown for all significant variables. —indicates data not applicable; NS indicates not significant in the multivariable model.
Only underlying diseases associated with significant risks are shown.
CMV serostatus was not available for 10 patient-donor pairs.
Factors entered into the model as time-dependent covariates.
The GVHD variable “missing” signifies patients who did not have data entered into the computerized system (n = 113). Acute and chronic GVHD were independently graded, as previously described.17 18 GVHD variables were not entered into the model for early IA.
P ≤ .05.
P ≤ .001.